Loading stock data…
ARCT
$8.63+0.01 (+0.12%)
Market ClosedLast close May 1
Arcturus Therapeutics Holdings Inc., a messenger RNA medicines company, focuses on the development of liver and respiratory rare disease therapeutics.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Arcturus Therapeutics Holdings Inc. in the Healthcare sector is trading at $8.63. The stock is currently near its 52-week low of $5.85, remaining 21.6% below its 200-day moving average. Technical signals show neutral RSI of 53 and bearish MACD signal, explaining why ARCT maintains its current current market pressure. The Whystock Score of 35/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Neutral momentum (RSI 53) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$8.63
Potential Upside
5%
Whystock Fair Value$9.06
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus10 analysts
Mean target$23.30+170.0%
Range$8.00 – $68.00
Fundamentals
Arcturus Therapeutics Holdings Inc., a messenger RNA medicines company, focuses on the development of liver and respiratory rare disease therapeutics. Its technology platforms include STARR, a self-amplifying mRNA technology platform, and LUNAR, a li...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$247.00M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
2.44
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-30.74%
Volume
Today's trading volume
311,692
Recent News
Illumina (ILMN) Tops Q1 Earnings and Revenue Estimates
Illumina (ILMN) delivered earnings and revenue surprises of +9.70% and +1.15%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
The widely followed investor has been buying stocks trading well below their all-time highs.
Arcturus Therapeutics Refocuses on Rare Disease mRNA Pipeline After COVID Vaccine Success at ROTH Conf
Arcturus Therapeutics (NASDAQ:ARCT) CEO Joe Payne told investors at the 38th Annual ROTH Conference that the company is refocusing on rare disease programs after gaining approvals for its COVID-19 vaccine in more than 30 countries. Payne said Arcturus had initiated a rare disease strategy for messen
These Are the Only 3 Stocks That Cathie Wood Bought Last Week
The growing investing icon was skimpy on her purchases last week, making the names she did buy that much more interesting.
Arcturus Therapeutics Teases 12-Week Phase 2 CF Study After Well-Tolerated Inhaled mRNA Dosing
Arcturus Therapeutics (NASDAQ:ARCT) Chief Executive Officer Joe Payne told investors at the Leerink Partners Global Healthcare Conference that the company has advanced its inhaled messenger RNA cystic fibrosis (CF) program through three Phase 2 cohorts and is preparing to initiate a longer 12-week s